

Québec: A Global Hub in Life Sciences and Health Technology



Québec Delegation @ BIO 2026 San Diego (44) - Booth #1717 ²

Pre-clinical and Clinical Research Partners (16)

- [Alsinova](#)
- [Biologics Manufacturing Centre](#)
- [Centre C3i Inc.](#)
- [Corealis Pharma Inc.](#)
- [Diex Recherche Inc.](#)
- [Dynacare](#)
- [GenAlz](#)
- [JSS Medical Research Inc.](#)
- [Nanofacile](#)
- [Neopharm Labs](#)
- [Nualtis](#)
- [Pharmascience \(Royalmount Biopharma Services\)](#)
- [Ropack Pharma Solutions Inc.](#)
- [Seriant](#)
- [Spectrum Pharma Packaging](#)
- [SpiroChem](#)

Biotech & Pharma (16)

- [9 BIO Therapeutics](#)
- [Anasens Inc.](#)
- [AstraZeneca Canada inc.](#)
- [Biocon Biologics Canada Inc.](#)
- [Eder Therapeutics](#)
- [Feldan Therapeutics](#)
- [Génome Québec](#)
- [Illumind therapeutics](#)
- [MISO CHIP](#)
- [Morphocell Technologies](#)
- [Neurenati Therapeutics](#)
- [Pendopharm](#)
- [Saguaro Biosciences](#)
- [SpeciLife Inc.](#)
- [Simmunome](#)
- [Telescope Therapeutics](#)

Support Organizations and Associations (12)

- [BIOQuébec](#)
- [Biotech City](#)
- [Catalis Québec](#)
- [CQDM](#)
- [Fonds FTQ](#)
- [Innovative Medicines Canada](#)
- [Lavery](#)
- [Linearis Ventures](#)
- [Montréal International](#)
- [Montréal InVivo](#)
- [Québec International](#)
- [Vffice Inc.](#)

Table of contents

01

Pre-clinical and
Clinical Research
Partners

02

Biotech & Pharma

03

Support
Organizations and
Associations



01 Pre-clinical and Clinical Research Partners

Description

Alsinova is A CRO combining an in-depth knowledge in clinical research with the use of cutting-edge technologies to address your challenges, including the co-creation of tailored and specific solutions.

Areas of application

- Clinical Research Innovation Through Connectivity
- Project Management and Strategic Development
- Site Monitoring and Management
- Data Management and Statistics
- Medical writing

Solutions

Alsinova offers three outsourcing models to fit your specific needs: The Insourced Consulting, the Classic Single Project, and Functional Service Provider models. Our models are tailored to your organization and financial objectives.

Strengths

At Alsinova, we understand the unique challenges and opportunities facing the biotech sector, and we specialize in delivering comprehensive solutions that align with the specific needs and goals of each client. With a relentless focus on connectivity, collaboration, and customization, we empower our partners to navigate the complexities of medical development and commercialization with confidence.



biologics
manufacturing
centre

6120 Royalmount Ave.
Montreal (Quebec) H4P 2R3
www.bmc-cppb.ca

BIO 2026 San Diego

Description

A fully integrated GMP facility providing Drug Substance (DS), Drug Product (DP), Quality Control (QC), Quality Assurance (QA) and Consulting services — guiding your biotherapeutic seamlessly from tech transfer to clinical and commercial manufacturing.

Areas of application

Cell-based biologics production (mammalian and insect bases mediums) ranging from vaccines (viral vector, protein subunit, virus-like particles) to diverse therapeutic proteins (antibodies, enzymes); and especially for phase 2 or 3 vaccines and therapeutic candidates maturing in clinical phases in addition to commercial Production.

Solutions

Fast, reliable biomanufacturing and analytical capabilities. We aim to fast-track your product development needs by rapidly producing clinical batches and be commercial production ready, helping you get to market faster.

Strengths

At the BMC, our experts bring over 20+ years of industry experience, combining a client-centric approach and a strong GMP culture to fast-track your journey from tech transfer to commercial success with precision and confidence.



5151 Bd de l'Assomption,
Montréal, QC
www.C3icenter.com

BIO 2026 San Diego

Description

C3i Center is an end-to-end advanced therapy manufacturing partner, supporting the full vein-to-vein lifecycle of cell and gene therapy products, from early development through GMP commercialization and providing access to precision medicine tools.

Areas of application

- Manufacturing
- Process Development & Tech Transfer
- Laboratory Testing and Validation Services
- Cryopreservation & Biobanking
- Cold Chain Logistics
- Biomarker and Assay Testing Services
- Companion & Complementary Diagnostics (CDx)
- Clinical Research Services

Solutions

C3i works closely with its clients to manufacture advanced therapies for patients worldwide. C3i is committed to delivering high-quality, compliant cell and gene therapy products on time, supporting improved patient outcomes and global regulatory approval. As a fully integrated CDMO, C3i develops, translates, and manufactures complex cell and gene therapies, with a strong track record of success enabled by seamless in-house, cross-functional collaboration. C3i is a global leader in precision medicine, enabling targeted access by bridging the gap between products and patients.

Strengths

Its strength lies in working with its partners to advance the industry's ability to bring cell and gene therapy research to market and make it accessible to patients in need.

“Its constant effort in manufacturing and testing is rewarded by giving patients another opportunity in life.”

Description

Contract formulation development and phase I/II/III clinical supplies manufacturing and packaging of pharmaceutical oral solid dosage forms.

Areas of application

Small and medium-sized companies (biotechs) or specialized pharmaceutical companies (Specialty Pharma) developing or wishing to develop solid oral dosage forms (i.e. tablets, capsules, powders, granules).

Solutions

For the development of drug products, we choose the best formulations and manufacturing processes adapted to the inherent properties of the active ingredient and the therapeutic application. Our competitors force the use of pre-established formulations and manufacturing processes to develop the drug products which is not optimal.

Strengths

In addition to our approach described above, we are recognized for the flexibility of execution of our contracts, the quality of our services provided by a team of experienced professionals who know how to judiciously adapt the development of the drug products according to the clinical phases and the therapeutic applications.

Description

Dedicated exclusively to clinical research, Diex Recherche conducts phase I to IV trials to pharmaceutical and biotechnology companies.

Areas of application

- CRO
- Pharmaceutical
- Biotechnology industry about to conduct a phase 1, 2 or 3 clinical trial

Solutions

Our very efficient and unique business model has been the key to our success! DIEX Recherche has built dedicated teams with specialized expertise to better serve our clients and patients. With fully equipped clinical research sites located in Sherbrooke (2), Québec City, Victoriaville, Joliette, and Trois-Rivières, DIEX Recherche offers a comprehensive platform with strong Phase I capabilities, including an 11-bed unit dedicated to early-phase clinical research, while supporting studies from Phase I through Phase IV.

Strengths

Expert in the conduct of clinical trials across multiple therapeutic areas, including vaccines, cardiology, psychiatry, women's health, cardiovascular, pulmonology, etc. DIEX Recherche understands sponsor and CRO needs and is recognized for its fast and reliable study start-up execution, consistently enabling early site activation and rapid readiness (4 to 6 weeks).

Description

At Dynacare, our services are as extensive as our history is deep. Our roots lie in providing essential medical testing that empowers patients and their physicians to better diagnose, understand and manage medical conditions. With a team of dedicated scientific and technical staff we are at the forefront of laboratory medicine – and can provide advanced diagnostics to meet your unique needs in a cost effective, timely and precise fashion.

Areas of application

- Precision medicine
- Molecular and Cellular Pathology
- Dermatology
- Gastrointestinal Pathology
- Uro pathology
- Breast Pathology
- Gynecopathology

Solutions

To provide the best healthcare possible for your patients, you need the latest and most effective diagnostic testing. That's why we are continuously investing in our laboratory technology to bring you the most innovative and advanced tests. Through Dynacare Next we are creating centres of excellence in pathology, genetics and pharmacogenetics to bring you the next generation of cutting-edge laboratory science.

Strengths

- Leader in Precision medicine
- Advanced Genetic Testing
- Digital Health
- Corporate Wellness Programs
- Mobile Testing
- Specialized services for the Insurance Industry.

Description

GenAlz unlocks the value of life sciences enterprise data, connecting systems with AI-powered intelligent solutions so teams can act with clarity, confidence, and speed. To do this, we've created a novel, ethical, and data compliant AI Solutions that massively increases workflow efficiency across pharmaceutical and life sciences applications.

Area of Applications

Good Practice (GxP) processes, including R&D and Manufacturing, of the lab-to-market process, specifically for teams looking to:

- Integrate and manage complex workloads with high volumes of highly variable data.
- Overcome limited success with AI.
- Improve organizational and staff AI skills.

Solutions

A novel, ethical, and compliant AI Solutions that massively increases workflow efficiency across pharmaceutical and life sciences applications by intermediating between an organization's internal information systems (data sources) and AI. The GenAlz platform includes Intelligent Solutions (out-of-the-box solutions for specific use cases and processes), Smart Functions (containerized AI and analytics capabilities), and a Software Development Kit (SDK).

Strengths

1. Keeps your data safe, because our software goes to the data, not the other way around, with data orchestration, containerization, dedicated AI and a virtual air gap.
2. The compliant and ethical AI choice, assuring adherence to GxP and regulatory compliance with whitebox and human-in-the-loop technology.
3. Enhances employee skills by making AI more accessible to core business process teams.

Description

JSS Medical Research is a full-service clinical research organization (CRO) with strong academic affiliations offering a wide range of services internationally. One of our distinguishing attributes is our methodological knowledge and expertise in the design and execution of complex clinical studies across therapeutic areas. These encompass all phases of development such as Phase I, II and III, as well as post-approval studies. The breadth of our experience enables our clients to collaborate with the same partner throughout the product lifecycle.

Areas of application

- Biotech
- Biopharma
- Medical devices

Solutions

The JSS team provides clients with a flexible, best-in-class approach to improve cycle times, attenuate costs and reduce risks. Experience in Phase I-III Clinical Trials ranging from small proof of concept to large complex multinational studies. Post-approval capabilities to support commitments to regulatory agencies, real-world evidence generation, and reimbursement.

Strengths

- Global coverage with offices in all major continents (North America, South America, Europe, Asia)
- Comprehensive services
- Full-service CRO
- 40 years in business



Nanofacile

1250 Guy Street, Montreal,
Quebec, H3H 2S7

www.nanofacile.bio

Description

Nanofacile accelerates RNA therapy development by providing biotech innovators with intuitive, easy-to-use tools for preclinical research and high-throughput screening. Our sterile, standalone consumables streamline formulation workflows, enabling faster and more efficient RNA therapy optimization.

Areas of application

Nanofacile's technology serves research laboratories, CROs, biotech, and pharmaceutical companies in:

- RNA Therapy Discovery, Development, and Optimization – Supporting every stage, from initial formulation to final refinement.
- High-Throughput Lipid Formulation Screening – Rapidly generating and optimizing lipid nanoparticle libraries.
- Targeted Therapies – Enabling precise RNA-based drug delivery to specific cells or tissues, enhancing efficacy while minimizing side effects.

BIO 2026 San Diego

Solutions

Nanofacile – Nanomedicine in a Box is a high-throughput (HT) RNA therapy formulation kit that empowers CROs, biotech firms, and pharmaceutical companies to develop RNA therapies efficiently and at scale. Designed as a ready-to-use, sterile consumable, it seamlessly integrates into any wet lab, simplifying proof-of-concept and formulation optimization.

Strengths

1. High-Throughput (HT) Screening Capability – Rapidly formulates and optimizes lipid nanoparticles (LNPs), accelerating RNA therapy development.
2. Standalone & Sterile Consumable – Requires no specialized infrastructure and integrates seamlessly into any wet lab.
3. Ease of Use – User-friendly design enables researchers to perform encapsulation workflows with minimal training.

Description

Neopharm Labs is a Canadian analytical laboratory founded in 1989.

All analytical, QC, R&D, Chemistry, microbiology, stability programs, and Life Sciences division services under one roof. 220+ experts, 2 GMP / FDA-inspected facilities delivering trusted, end-to-end scientific certainty.

Areas of application

- Analytical Chemistry Testing
- Microbiology Analytical Testing
- Stability Testing
- Research & Development
- Impurities Risk Assessment
- Life Sciences

Solutions

Neopharm offers expert analytical services for the life sciences industry. We provide reliable GMP quality control testing and innovative R&D solutions to accelerate product development and improve people's lives.

At Neopharm Labs, we offer a comprehensive suite of services that cover every stage of the product lifecycle. Our extensive range of analytical solutions expedites the journey from concept to commercialization.

Strengths

We conduct over 8,000 tests each month in our state-of-the-art facilities, combining agility and accessibility to address complex analytical and regulatory challenges.

Description

Nualtis Corp. is a Quebec-based pharmaceutical company specializing in proprietary oral thin film (OTF) drug delivery for human and animal health, partnering with pharma innovators worldwide.

Areas of application

- Human health (CNS, neurodegeneration, psychedelics)
- Specialty generics & lifecycle management
- Animal health (companion animals)
- Consumer / OTC products

Demo

Product samples available at booth.

Solutions

Human and animal platforms deliver fast-onset, water-free, palatable medications with enhanced bioavailability, supported by integrated R&D, analytical, regulatory, and cGMP manufacturing services.

Strengths

- Over 30 US patents and 20+ years of OTF formulation expertise.
- OTF breakthroughs including 10x bioavailability gains, 100mg+ API loading, 6h+ sustained release platform, first-in-class animal health application, and matching IV infusion performance
- FDA- and Health Canada-inspected cGMP plant from pilot to multi-million-unit scale with approved products in commercial stage.
- Diversified portfolio across therapeutic areas in human and animal health, partner types, and stages of development.
- Strategically located in Canada, offering equivalent quality and expertise at lower cost than US-based facilities.

Description

For over 30 years, Pharmascience Royalmount Laboratories has been conducting regulated and non-regulated bioanalysis. With over 300 FDA/EMA/HC compliant bioanalytical methods, and industry's highest reliability / lowest reanalysis rates of <2%, this makes us a great, cost-effective, partner-of-choice for your bioanalytical programs.

Areas of application

- Bioanalytical method development, validation and quantitation of drugs and metabolites in biological fluids and tissues
- Biomarker assays for assessing the activity of candidate therapeutics covering a wide range of therapeutic areas
- TK and PK statistical reporting in support of preclinical and clinical programs

Solutions

- 2 Hamilton robotic systems
- 12 LC-MS/MS
- 2 Agilent (BioTek) Synergy Neo2 Hybrid Multimode Plate Readers with AlphaLISA and AlphaScreen capabilities
- Luminex INTELLIFLEX SR Multiplex platform with xMAP® Technology
- Standards Council of Canada (SCC) certified FDA audited laboratory

Strengths

- Responsiveness and reliability - Reply within 1 day
- Reporting – Guaranteed on-time
- Method development - Start within 2 weeks
- Validation - Start within 1 week of method development



10801, rue Mirabeau,
Montréal Est (Québec) H1J 1T7
www.ropack.com

BIO 2026 San Diego

Description

Solid oral dose contract manufacturing and packaging for the pharmaceutical industry.

Areas of application

- Pharmaceutical;
- Nutraceutical;
- Food industries.

Solutions

Develop, innovate and optimize oral solid dose tech transfer, manufacturing, primary and secondary packaging services for the pharmaceutical, nutraceutical and food industry. Offering high quality made to specification products in powder, tablet and capsule format packaged in bottles, blisters, sachets and stick-packs.

Strengths

Reliability, (95% + service levels) flexibility and quality. Over 45 years of experience and continuous improvement in operational, technical and quality know how across our sites. International Serialisation Hub as well as 2D coding on all our production lines.



4945 Beaubien Street East
Montreal (Quebec) H1T 1V1
[Seriant.org](https://seriant.org)

BIO 2026

San Diego

Description

Full-service Clinical Research Organization (CRO) partnering with biotech, pharma, medtech, and academia to deliver high-quality clinical trials with scientific rigor and operational excellence.

Areas of application

- Phase 1 to 4 clinical trial services
- Complex, multicentric, global studies
- Decentralized Clinical Trials (DCTs)

Solutions

Clinical research support across all phases, combining scientific expertise, operational agility and decentralized solutions to deliver scalable, participant-centered trials with end-to-end oversight.

Strengths

With over 25 years of experience, Seriant was founded at the Montreal Heart Institute and continues to expand beyond cardiology, helping shape clinical research in precision medicine, metabolic disorders, oncology, and more. Our Montreal-based bilingual team provides personalized services leveraging in-house DCT technology, a biobank, a CAP/CLIA-certified pharmacogenomics lab, and preventive health centers.

Description

Spectrum participates in the growth of the sector by supporting innovative companies by offering unique expertise in clinical trial supply chain management, both nationally and internationally. The services offered include primary and secondary packaging, labeling, warehousing and worldwide distribution of products under investigation in Phase I, II and III. With his FDA and Health Canada licence we are the distribution center of choice in North America and also have a depot in France and Australia to support your projects.

Areas of application

- Packaging of pharmaceutical and natural health products;
- Clinical Trial Supply Chain and Logistic Management

Solutions

The services offered include primary and secondary packaging, labeling, warehousing and worldwide distribution of products under investigation in Phase I, II and III. With his FDA and Health Canada licence we are the distribution center of choice in North America and also have a depot in France and Australia to support your projects.

Strengths

Our state-of-the-art facilities allow us to provide our clients with comprehensive and highly customizable service, according to the strictest industry requirements.

BIO 2026 San Diego

Description

Cyclenium is a pioneering research partner providing innovative solutions across the drug discovery and process R&D chemistry value chain.

Area of applications


- Medicinal Chemistry
- Macrocycles
- ADC
- Process R&D including HTE platform

Solutions

Cyclenium delivers integrated discovery chemistry solutions, from novel fragment libraries to optimized bioactive molecules and early CMC, accelerating drug development with efficiency, precision, and flexibility.

Strengths

Cyclenium strengths lie in its end-to-end discovery chemistry expertise, combining innovative proprietary libraries with advanced design technologies and high-quality synthesis. Its integrated platform, from fragment discovery to early CMC, enables efficient, tailored solutions, accelerating the development of bioactive molecules with precision, flexibility, and scientific excellence.



02 Pharma & Biotech



2325 rue de l'Université
Québec, QC
<https://9bio.ca/>

BIO 2026 San Diego

Description

9Bio is a protein engineering company developing next-generation biologics through structure-guided design and computational modeling. Rather than generating antibodies de novo, we re-engineer validated molecular frameworks to reprogram binding and functional properties for new therapeutic applications.

Areas of application

- Engineering of improved specificity and affinity
- Multifunctional biologics with defined binding logic
- Conditionally active proteins responsive to disease environments (e.g., tumor pH)
- Optimization of developability, including stability, manufacturability, and delivery

Solutions

9Bio applies an iterative, structure-guided design workflow combining ultra-high throughput structural modeling, molecular dynamics, and experimental validation to redesign protein interfaces. This enables precise control over epitope engagement, affinity tuning, and conditional or multi-functional behavior while preserving favorable biophysical properties.

Strengths

- Ability to engineer conditional, multi-parameter, and logic-based binding behaviors not otherwise possible
- Framework-level reprogramming of antibody functionality
- Integration of computational modeling with experimental validation
- Proven applicability across biologic modalities (antibodies, cytokines, etc)

Description

Deep-tech company developing a rapid, quantitative, connected DNA nanotech-based platform for biological samples, enabling analysis at home, bedside, or elsewhere.

Areas of Applications

- Therapeutic drug monitoring (TDM)
- Multiplex biomarker panels
- Decentralized chronic disease monitoring
- Oral Fluid Drugs-of-abuse Testing



Solutions

Portable platform for multiplex TDM and biomarker measurement from saliva or a drop of blood, delivering quantitative results and digital connectivity in decentralized settings.

Strengths

- Rapid, portable and connected platform
- Lab-quality quantitative results in minutes
- Multiplexing up to 8 targets simultaneously
- Fast adaptation of available tests to new TDM + biomarker use cases
- Compatible with blood and saliva workflows

Description

AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.

Areas of application

Its focus is on the following core therapy areas: Cardiovascular, Renal and Metabolic diseases (CVRM); Oncology; Rare Disease; Respiratory & Immunology; and Vaccines & Immune Therapies.

Solutions

AstraZeneca Canada works to research, develop, and market innovative medicines. AstraZeneca Canada was recently designated a global Clinical Hub for oncology and immuno-oncology clinical studies and is currently leading global oncology clinical studies in lung, head, and neck cancer.

AstraZeneca Canada believes the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of its business and its purpose.

BIO 2026

San Diego

Description

A unique, fully integrated global pure play biosimilar enterprise driven with a sense of purpose to impact millions of patients worldwide.

Areas of application

- Biosimilars
- Generics
- Manufacturing & Commercialization

Solutions

Biocon Biologics is driven by a strong sense of purpose and the unwavering commitment to serve patients and healthcare systems across the globe by unlocking equitable access to high quality biosimilars.

Strengths

A unique global portfolio of biosimilars ranging from insulins to recombinant proteins and monoclonal antibodies with a high-level scientific research expertise.

Biocon has a global production with high quality and compliance standards.

With more than 20 biosimilars approved or in development Biocon has 8 biosimilars commercialized in Canada.

BIO 2026

San Diego

Description

Canadian biotech advancing precision genetic medicines for rare and cardiometabolic disease, and the dedicated Canadian commercial partner for global innovators in rare and severe disease.

Areas of application

- WES discovery: founder-population protective variants advancing as partnerable RNAi and biologic targets
- AAV gene therapy: IND-enabling lead program for LPLD
- Canadian launch partner: in-licensing rare and severe disease assets with partner-exclusive launch teams
- Built-in credibility: an active Canadian R&D operator with insider access to regulators, payers, and KOLs

Solutions

Partners on genetically validated AAV and WES programs, or engages Eder to launch rare and severe disease assets through its Canadian commercial platform.

Strengths

Exclusive NRC license to next-generation AAV8 vector, chosen by the Government of Canada to commercialize federal gene therapy. Saguenay founder-effect population powers our WES discovery engine. Leadership with 60+ specialty and rare-disease launches across cardiology, neurology, endocrinology. Partner-exclusive commercial model with buy-back option, founder-level accountability.



2666 Bd du Parc Technologique
Suite 290, Québec, QC
www.feldan.com

BIO 2026

San Diego

Description

Feldan Therapeutics is a clinical biotechnology company developing leading-edge treatments based on its proprietary peptide-based intracellular delivery technology, the Feldan Shuttle platform. The Shuttle's ability to bind to cell membranes and to disrupt nascent endosomes enables the delivery of small molecules, proteins, nuclease complexes, peptides and antisense oligonucleotides (ASOs) inside cells. Feldan's lead program, is an intralesional drug composed of a Shuttle and an ASO targeting Gli1, the master regulator of the Hh pathway.

Areas of application

- Biotechnology
- Pharmaceutical

Solutions

BCCs are caused by the activation of the Hedgehog (Hh) pathway; in that context, Feldan's lead program, FLD-103, is a novel drug composed of a Shuttle and a antisense oligonucleotide targeting Hh in the cytoplasm. It will be administered via intralesional injections in BCC tumors to slow or revert their growth. In parallel to its lead program, Feldan is currently developing therapeutic indications for pulmonary diseases using nucleases and (mainly) ASOs.

Strengths

Feldan Shuttle technology is an innovative platform that has demonstrated its effectiveness in several proofs of concept over the past few years. We have demonstrated its effectiveness in delivering different molecules and into various organs. The flexibility of the platform increases the collaboration potential of the company.

Description

Génome Québec, a non-profit organization, was established in 2000. Since its inception, it has helped Québec make great strides in genomics research. Over the years, projects funded by Génome Québec and its Innovation Centre have made significant contributions to many areas of activity. That is why genomics is now considered to be the great white hope of economic development, particularly in health, agrifood, forestry and the environment.

Areas of application

- Biotech
- Biopharma

Solutions

Genomics-based innovations will provide equitable and inclusive solutions to help meet health challenges, as well as environmental, technological, societal and public policy issues.

Strengths

We are recognized for our agility, high standards of excellence, multi-sector omics expertise, variety of our funding programs, and our internationally renowned sequencing, genotyping, and gene expression services.



1460 rue de l'église, Suite 200,
Montréal, Québec, H4L 2H6

www.illumindtherapeutics.com

Description

Illumind Therapeutics is a Montreal-based biotechnology startup specializing in transforming PTSD treatment by targeting dysregulated brain circuits through the repurposing of small molecules.

Our approach focuses on the prefrontal-hippocampus-amygdala pathway, utilizing innovative pharmacology to modulate glutamate and GABA circuits.

By leveraging drugs already proven safe in Phase I/II trials, we aim to accelerate clinical development timelines while addressing the underlying pathophysiology of mental health disorders.

BIO 2026

San Diego

Areas of application

- PTSD - Primary Focus
- Resistant Anxiety - Secondary Target
- Neuropsychiatry - Broader Field

Solutions

1. **Brain Circuit Targeting:** Focuses on the prefrontal-hippocampus-amygdala pathway
2. **Glutamate/GABA Modulation:** Dual-pronged pharmacology for balance
3. **Drug Repurposing:** Molecules with established safety profiles
4. **Accelerated Timeline:** Targeted Phase II study



207-6750 Hutchison St
Montreal (QC) H3N 1Y4
<https://misochip.com/>

BIO 2026 San Diego

Description

Drug discovery services for *ex vivo* testing of cancer drugs on live human tumor tissues. Enabling biotechs to assess efficacy and mechanism of action in the real tumor microenvironment (TME).

Area of applications

- Efficacy & Mechanism of Action Studies
- Drug Combination Strategies
- Data Sets Generation for AI/ML Models
- Indication Prioritization

Patient-Derived Tumor Explants

Our platform enables the test of multiple drugs, side-by-side, on human tumor fragments with their native TME preserved and the response analysis with multi-omics & spatial biology.

Maximizing Insight from Human Tissues

- Access to live human tumors for research purposes
- 5x greater throughput → 15 to 30 tests per tumor sample
- 5x longer viability *ex vivo* → 15 days
- Increased tissue density per FFPE block to reduce cost of spatial biology
- Cancer models: Cancer of ovary, uterin, brain, kidney and lung.



275 Boul. Armand-Frappier,
Laval, QC

<https://www.morphocell.com/>

Description

Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its stem cell-derived engineered tissues for organ replacement therapy. Through an allogeneic approach, strong preclinical data in small and large animals and key hurdles in manufacturing already de-risked, Morphocell is rapidly approaching the clinical phases. ReLiver®, our lead product, is an implantable, fully mature, engineered liver tissue that allows for the allogeneic treatment of acute and acute-on-chronic liver failure (a \$14B market), without the need of immunosuppression. Supported by a \$40M series A round and strong partnerships, ReLiver is now less than 30 months away from a first-in-human clinical trial. With 24 FTE, a solid IP position and new state-of-the-art HQ and laboratories, Morphocell established its leadership in the liver cell therapy space.

BIO 2026 San Diego

Areas of application

- Biotechnology
- Regenerative Medicine
- Stem Cell Therapy
- Liver Disease

Solutions

Morphocell's first therapeutic product, ReLiver®, allows for the allogeneic treatment of acute and acute-on-chronic liver failure.

Transient implantation of ReLiver® results in improved survival, treats hepatic encephalopathy and accelerates the recipient's liver regeneration, all without the need of immunosuppression.

Strengths

Morphocell significantly de-risked the technology, collected compelling preclinical efficacy and safety data and addressed key hurdles in process development.



630 René-Lévesque Blvd W.
Montreal, QC
<https://www.neurenati.com/>

Description

Based in Montreal, Neurenati Therapeutics is a pioneering biotechnology company developing an innovative treatment for Hirschsprung disease.

Areas of application

- Pediatric rare diseases
- Gastroenterology
- Hirschsprung's disease

BIO 2026 San Diego

Solutions

Via rectal administration, this treatment aims to promote the regeneration of the enteric nervous system which is otherwise missing from the colon of patients, most of them being young children. The therapy is designed to also globally improve intestinal functions in these children, thereby offering significant hope for their well-being.

Strengths

Its innovative approach is based on regenerative medicine, offering a non-surgical alternative. It has demonstrated that Glial Cell-Derived Neurotrophic Factor (GDNF), administered via rectal enema, stimulates the formation of a new enteric nervous system in the colon of three Hirschsprung's disease mouse models. This newly created enteric nervous system significantly improves gastrointestinal functions, prolonging the life of a significant proportion of these mice. Recent data demonstrate that GDNF, in addition to its beneficial effects on the formation of the enteric nervous system, also exerts a positive influence on the overall intestinal ecosystem.

Description

Pendopharm, a division of Pharmascience, is a leading Canadian specialty pharmaceutical company dedicated to developing, in-licensing and commercializing innovative products to improve the lives of Canadian patients and their families.

Area of applications

- Gastroenterology
- Sports Medicine & Orthopedics
- Neurology
- Specialty Medicine

The company has a portfolio of established medicines, offering more than 40 products across multiple therapeutic areas.

Solutions

Pendopharm is actively seeking to in-license or acquire late clinical to commercial stage assets for Canada and potentially other territories. We believe that our proven track record, and well-established commercial infrastructure and strong financial capabilities make us the ideal partner to maximize the value of your products.

Strengths

- Fast decision-making
- Collaborative and flexible partnership structures
- Strong alliance management
- In-house expertise across all functional areas
- Commitment to commercial success of products

BIO 2026

San Diego

Description

Saguaro Biosciences provides an integrated live-cell profiling platform powered by proprietary non-perturbing dyes, delivering high-fidelity kinetic biomaps to accelerate drug discovery programs.

Areas of application

- Drug Discovery
- Safety Assessment
- Complex In Vitro Models

Solutions

We combine our non-perturbing dye technologies with deep learning analytics to map functional cellular responses, enabling partners to identify drug mechanisms and toxicities in native-state models.

Strengths

- High-fidelity data: Our non-perturbing, environment-sensitive dyes capture high-density functional signatures while maintaining native-state behavior in iPSCs and 3D models.
- Functional kinetic mapping: Captures the trajectory of functional responses over time for superior mechanism of action characterization.
- Proven Scalability: A validated 3,000-compound benchmarking



11-105 Querbes Avenue
Montréal (QC) H2V 3V8
www.specilife.com

Description

SpeciLife is a biospecimen sourcing hub supporting pharma and biotech teams, with a boutique approach focused on feasibility, quality, and tailored sample access.

Area of applications

- Oncology
- Infectious diseases
- Autoimmune diseases
- Neurological disorders
- Rare diseases

BIO 2026

San Diego

Solutions

Access to high-quality human biospecimens (FFPE, fresh/frozen tissues, biofluids, cells, and derivatives) through a curated global network, delivered with a high-touch, boutique, tailored approach.

Strengths

High-touch, boutique approach with strong responsiveness and scientific engagement.

Global network of hospitals, clinics, academic institutions, and biobanks/biorepositories.

Deep expertise in feasibility and study alignment.

SpeciLife is a trusted partner, connecting pharma and biotech teams to tailored, high-quality biospecimens.



211-825 Boul. René-Lévesque E
Montréal, QC H2L 0A1 Canada
www.simmunome.com

Description

Simmunome is a TechBio company enhancing the predictability of clinical drug development to prevent late-stage failures by predicting patient outcomes sooner, for every patient.

Areas of application

- Advanced data analysis
- Clinical decision support
- Disease management

Demo

Click [here](#).

BIO 2026 San Diego

Solutions

Multi-omic disease simulations to elucidate disease mechanisms, validate drug targets, and predict patient responders, from sub-population to single-patient level.

Strengths

- Hybrid Approach combining mechanistic modeling with ML. By abiding biological rules, it surpasses traditional methods and pure data-driven approaches in reliability.
- Transparency of results enabling tracing of every interaction that influences calculated efficacy profiles.
- Disease-Agnostic disease models across therapeutic areas, allowing comparisons across diseases and pivoting to high potential indications.

Description

Telescope Therapeutics is a Montreal-based biotechnology company developing first-in-class antifibrotic therapies by targeting GPCR using human-relevant iPSC-derived disease models.

Areas of application

- Fibrotic diseases (heart, kidney, lung)
- Drug discovery and translational models
- Heart Failure, HFpEF, Aging, Diabetes, Chronic Kidney Disease

Solutions

Telescope Therapeutics develops therapies that modulate fibrosis at its biological source by targeting G protein-coupled receptors (GPCRs). By combining advanced receptor pharmacology with human induced pluripotent stem cell (iPSC)-derived fibroblasts and organoids, the platform enables the identification of compounds that prevent pathological tissue scarring while preserving normal wound healing. This approach aims to deliver first-in-class treatments for diseases driven by fibrosis.

Strengths

Telescope Therapeutics integrates precision GPCR pharmacology with human-relevant disease models to improve translational predictability in drug development. Using advanced biosensor technologies and human iPSC-derived cardiac fibrosis models, the company identifies biased ligands and develops peptide and small-molecule candidates targeting fibrotic pathways, with the goal of delivering first-in-class antifibrotic therapies while reducing clinical failure risk.



03 Support Organizations and Associations

Description

BIOQuébec is a non-profit association entirely funded by its members. It brings together more than 360 companies and organizations active in Québec's life sciences and health technologies industry. Our members operate across the full health innovation continuum and play a significant role in improving quality of life. Their activities span the discovery of drugs, vaccines, diagnostic tools, and medical technologies (equipment and supplies), as well as their development, manufacturing, and commercialization. BIOQuébec serves as the voice of the industry, fosters connectivity and economic development, and acts as a strategic bridge between the private sector and key stakeholders.

Areas of application

- Advocacy & Lobbying
- Networking & Personalized Connections
- Business development initiatives and partnerships
- Lifescience Industry Information source

Solutions

BIOQuébec provides the industry with an action-oriented forum to address challenges and seize opportunities within the business environment. By facilitating the sharing of information and connections, the association creates significant value for its members. Through strategic partnerships with similar associations in Canada and abroad, BIOQuébec fosters collaboration opportunities, helping life sciences companies scale and compete on a broader stage. Additionally, agreements with privileged suppliers offer exclusive discounts and benefits on a wide range of services and products.

Strengths

Credible, nimble and proactive, has deep roots within the Québec and Canada ecosystems and is very well connected with members and stakeholders.



1333, boulevard Chomedey
bureau 401, Laval
<https://www.citebiotech.com/>

BIO 2026

San Diego

Description

The Biotech City is a biotechnology and life sciences hub of the Metropolitan Montréal including world renowned biopharmaceutical firms and research institutes employing more than 5,000 individuals.

Areas of application

- Implementation or expansion project
- Promotes networking among businesses, investors, research institutes and government agencies
- Organizes and participates in biopharmaceutical sector events
- Represents the life sciences sector on a local and international level

Solutions

Our mission is to ensure the attraction, development and growth of corporations born out of health science research and to provide them an environment conducive to success.

Created by a partnership between the City of Laval and the INRS Armand-Frappier Santé Biotechnologie Research Centre (INRS), the Biotech City is a hub of knowledge where exceptional inter-university collaboration and science companies converge for research, training and commercial development.

Strengths

Working together with the research institutions on its territory, the Biotech City helps resident companies innovate and become more competitive.



CATALIS<sup>MD
TM</sup>
Recherche clinique Québec
Clinical Trials Quebec

465 McGill Street, Suite 200
Montreal, Quebec
www.catalisquebec.com

Description

CATALIS Quebec is an independent, non-profit organization, formally mandated and funded by the Government of Quebec to drive and coordinate provincial efforts in clinical research, ensuring that Quebec stands out internationally for the excellence and performance of its research environment. Acting as a neutral facilitator, CATALIS collaborates with a large network of public and private partners to accelerate the development of innovative treatments for patients while maximizing private investment in Quebec.

Areas of application

- Biotech
- Biopharma
- Clinical research

BIO 2026 San Diego

41
[Back Québec Delegation](#)

Solutions

The CATALIS Network brings together nearly 100 public and private partners to elevate Quebec's clinical research ecosystem and strengthen its leadership at the international level. By aligning strategies and generating innovative solutions, CATALIS streamlines research approval processes, promotes collaboration, and fosters a patient-centered research environment. As part of this effort, CATALIS created the FAST TRACK Evaluation Service which aims to authorize clinical trials in ≤ 8 weeks, a reduction of nearly 75% of the standard authorization time. CATALIS also launched Clinical Trials Quebec (CTQ), a provincial public information hub on clinical research for the population, offering educational content, a Personalized Support Service to help patients find a clinical trial, and much more. To further support industry stakeholders, CATALIS developed CTQ for Sponsors, a dedicated platform designed to facilitate trial feasibility, site identification, and navigation of Quebec's clinical research environment.

Strengths

- Accelerated clinical trial approvals
- Strong public-private collaboration
- Government-backed initiative ensuring stability and long-term impact
- Commitment to patient engagement and access to innovation
- Medical, scientific and data research expertise



Centre d'Affaires REGUS,
1800, 500 Pl. d'Armes
Montréal, QC
www.cqdm.org

BIO 2026 San Diego

Description

CQDM is a non-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D that accelerates translation of leading-edge discoveries into vaccines, therapeutics and diagnostics addressing unmet medical needs while generating significant benefits for the Canadian economy.

Areas of application

- Biopharmaceutical research

Solutions

As an established partner of federal and provincial governments, industry, and academia, CQDM deploys R&D funding programs that focus on accelerating the translation of innovation into socio-economic outcomes and health benefits for our population. Our value proposition is articulated as follows: A unique business-led and purpose-driven collaborative model that brings together the private and the public sector to translate innovation into economic outcomes and health benefits.

Strengths

- Wide range of programs
- Turnkey projects

Description

The Fonds de solidarité FTQ is a source of pride in Québec, fulfilling its mission through a business model created more than 40 years ago. Since then, the Fonds has rallied Québec into action thanks to the retirement savings of 795,374 shareholders.

Areas of application

With net assets of \$21.7 billion as of November 30, 2024, the Fonds supports nearly 4,000 companies through direct and indirect venture and development capital investments based on the belief that impact is created as much by financial as societal returns. The Fonds support Quebec SMEs in the long term and at all stages of their development to ensure sustainable growth for local businesses.

Solutions

The Fonds' mission has been based on a unique model: investing workers' savings in local businesses to stimulate the Québec economy. As a key stakeholder in Québec society, the Fonds wants to have a positive impact and is committed to helping Québec businesses create value for all of us. The Fonds invest in growing and developing businesses.

Strengths

In addition to financial support, its experts can help you plan your digital transformation, develop your business intelligence, make structural and organizational changes, update your corporate governance, and more.

Leveraging its expertise, capital, and extensive network, The Fonds serves as the essential strategic partner for providing all necessary resources to successfully execute your projects.

Description

Partnering to champion policies that drive the discovery, development and delivery of transformative medicines and vaccines.

Areas of application

Our member companies, which range from early-stage startups to established organizations, are revolutionizing healthcare through the discovery and development of new medicines and vaccines.

Solutions

We achieve our goals by forming alliances, supporting policies, improving Canada's regulatory environment, widening access to innovative medicines and ensuring the effective protection of intellectual property.

We believe in ensuring that Canadians have access to the innovative treatments they need. Our activities are a fundamental part of safeguarding our healthcare system for future generations.

Strengths

Guided by a strict Code of Ethical Practices, we work with governments, insurance companies, healthcare professionals and other stakeholders to advance the field of pharmaceutical research and development and enhance the wellbeing of Canadians.

Description

With a team of over 200 professionals – including lawyers, notaries, trade-mark agents and patent agents – Lavery is committed to delivering a **one stop legal shop in the Province of Québec** – also known as a **360° legal approach**.

Areas of application

- Artificial Intelligence
- Energy and Natural Resources
- Financial Services
- Health and Social Services
- Infrastructure
- Insurance
- Intellectual Property
- Life Sciences
- Manufacturing
- Sports and Entertainment
- Technology
- Transport

Solutions

With respect to the life sciences sector, our team have been pioneers in managing the regulatory and contractual activities and intellectual property of public institutions, corporations and organizations in Québec's life sciences sector. Our team advises biotechnology and pharmaceutical companies in the context of various agreements, such as license agreements, supply agreements, subcontracting agreements, manufacturing contracts, distribution agreements, service agreements, marketing agreements, joint ventures and financing agreements.

Strengths

Lavery has been named the Quebec Law Firm of the Year by several editions of the Canadian Law Awards and ranks 1st among Quebec's leading independent law firms according to the Top 10 Quebec Regional Law Firms by Canadian Lawyer magazine.

Lavery is a member of the World Services Group (WSG), an international network of law firms and other professional service providers in more than 145 jurisdictions.



600-1020 Rte de l'Église,
Québec, QC
<https://www.linearis.com/>

Description

Linearis with its tandem Ventures Fund and Laboratory is pioneering and supporting discoveries to prevent, detect, and cure metabolomic diseases including cancer & diabetes through direct investments in innovative AI-powered life sciences companies.

Areas of application

- Chronic conditions (cardiac, cancer, diabetes, metabolomics, etc.)
- AMR
- Water analysis (for contaminants and pathogens)

Demonstration

Video: [Linearis Lab \(Vimeo\)](#)

BIO 2026 San Diego

46
[Back Québec Delegation](#)

Solutions

Linearis with its tandem Ventures Fund and Laboratory is pioneering and supporting discoveries to prevent, detect, and cure metabolomic diseases including cancer & diabetes through direct investments in innovative AI-powered life sciences companies.

Linearis Ventures leverage its AI and multi-omics expertise to support life science companies' growth, accelerating their trailblazing innovation and advancing biomarkers to provide critical insights into a broad spectrum of health conditions.

Linearis Labs provide services to large biobanks, CROs and BioPharma companies across their life cycle management from drug discovery, patient screening, disease prevention as well as treatment monitoring.

Strengths

Our innovative combination of AI + high throughput large panel analysis of > 1,500 metabolites provide rapid reporting as well as disease signatures across various usages in life sciences as well as water analysis

Description

Greater Montréal's economic promotion agency, for the past 25 years, Montréal International (MI) has contributed to building Greater Montréal's international reputation and prosperity by acting as a driving force for economic development.

Areas of application

- Life sciences and health technologies
- Clean technology
- Artificial intelligence
- Aerospace
- Video games
- Other sectors

Solutions

Its mandate is to attract direct foreign investment, international organizations, entrepreneurs, talented workers and international students to the region. Our team consists of 80 professionals with specialized expertise, including in the divisions of Talent Montréal (attracting international talent) and I choose Montréal (attracting and retaining international students).

Strengths

- 80 professionals who are specialists in their field
- Strong network with major partners

Description

Montréal InVivo represents the Life sciences and Health Technologies (LSHT) cluster of Greater Montréal. We are a non-profit economic development organization that aims to create a business environment that fosters innovation, growth, and competitiveness of public and private organizations within the LSHT sector.

Areas of application

- Biotech
- Biopharma

Solutions

With the ongoing intention of promoting and fostering the economic development and growth of the life sciences and health technologies sector in Quebec, Montréal InVivo hosts on its website a tool built by Fundica that will help you find the perfect financing program for your business.

Strengths

- The catalyst and promoter of innovative, forward-looking and high-impact projects to further develop the sector
- The privileged independent interceder of the public authorities

BIO 2026 San Diego

Description

Québec International promotes Québec City's economic growth and global presence, collaborating with partners worldwide to support entrepreneurs, professionals, and investors by overcoming obstacles and guiding development.

Areas of application

- **Biopharmaceuticals:** Biotechnologie & Pharma
Vaccins, Infectiologie, Cancer, Cardio, Pneumo, Obesity, Neurosciences, Precision medicine. OMICs sciences.
- **Medical Technologies:** Medtech & e-Health
Diagnostics, Ai & data sciences, Handicap, IoT, Silver economy
- **Natural Health Products:** Nutraceuticals & Cosmetics
Boreal Ingredients, Personalized skincare,

Solutions

We boosts Québec City's life sciences and health tech industry, acting as a global ambassador, fostering collaboration, innovation, and solutions to advance the sector's recognition and growth worldwide

Strengths

9 200 jobs
205 companies
1,3 billion sales
84 R&D centres, chairs and research laboratories
Tax rates among the lowest in North America
Lowest electricity rates in Canada and 99% clean energy
2nd city with lowest operating costs in Canada



3135 Bd Moïse-Vincent #201,
Saint-Hubert (Québec) J3Z 0G7
www.vffice.com

Description

VFFICE is a Microsoft Cloud Solutions Partner specializing in Enterprise Software, including ERP, CRM, BI, and Custom Development for the Pharma and Life Sciences Industry. We serve clients globally promoting growth and digital transformation with a dedicated focus on the Microsoft platform and AI.

Areas of application

- Pharma & Life Sciences
 - CROs, CDMOs, R&D Organizations
 - Pharma Manufacturing
 - Pharma Distribution
 - Private Equity in Pharma
- Food & Beverage
- Industrial
- Financial Services

Intro video

[Presentation - VFFICE Boost for Pharma](#)

BIO 2026

San Diego

Solutions

VFFICE provides innovative Microsoft-based solutions for life sciences sector. Our advanced data analytics, and automation tools enhance traditional ERP, ensuring better compliance, reporting, batch and inventory tracing, quality control, formulation management, LIMS integration, real-time insight, financial visibility and embedded AI.

We empower pharmaceutical companies achieve breakthroughs in R&D, drug discovery, diagnostics, biomanufacturing, and distribution.

Strengths

VFFICE is recognized for its extensive Microsoft Cloud and Business Solutions expertise, providing customizable solutions to address complex challenges. Our team includes experts with over 25 years of experience in the pharmaceutical industry, ensuring deep industry knowledge and insights. We are known for our flexibility, resourcefulness, and commitment to delivering projects on time and on budget.

Thank you

InvestQuébec.com



Rachel Banville
Trade Advisor, Life sciences
Rachel.Banville@invest-quebec.com
418 731-1887



Noah Ouellette
Commercial Attaché – Life sciences and
Innovation, Québec Government Office in
Boston
Noah.Ouellette@mri.gouv.QC.ca
617-901-5914



Old Québec
© Tourisme Québec / Francis Gagnon